Stamford

Stamford Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative topical therapies for the treatment of skin cancers, particularly non-melanoma skin cancers such as basal cell carcinoma (BCC). The company's lead candidate, SP-002, is a topical formulation of a potent Hedgehog pathway inhibitor designed to provide a non-surgical alternative for patients with localized lesions. By utilizing a localized delivery approach, Stamford aims to achieve high therapeutic concentrations at the site of the tumor while minimizing the systemic side effects often associated with oral Hedgehog inhibitors. The company's mission is to improve patient outcomes and quality of life through advanced dermatological drug delivery technologies.